Publicacións nas que colabora con Laura Fernández García (42)

2024

  1. Improving phage therapy by evasion of phage resistance mechanisms

    JAC-Antimicrobial Resistance, Vol. 6, Núm. 1

  2. Single-cell analysis reveals that cryptic prophage protease LfgB protects Escherichia coli during oxidative stress by cleaving antitoxin MqsA

    Microbiology spectrum, Vol. 12, Núm. 2, pp. e0347123

  3. Toxin/antitoxin systems induce persistence and work in concert with restriction/modification systems to inhibit phage

    Microbiology spectrum, Vol. 12, Núm. 1, pp. e0338823

2023

  1. CRISPR-Cas13a-Based Assay for Accurate Detection of OXA-48 and GES Carbapenemases

    Microbiology spectrum, Vol. 11, Núm. 4, pp. e0132923

  2. Molecular studies of phages-Klebsiella pneumoniae in mucoid environment: innovative use of mucolytic agents prior to the administration of lytic phages

    Frontiers in Microbiology, Vol. 14

  3. Proteomic Study of the Interactions between Phages and the Bacterial Host Klebsiella pneumoniae

    Microbiology Spectrum, Vol. 11, Núm. 2

  4. Ribosome inactivation by Escherichia coli GTPase RsgA inhibits T4 phage

    Frontiers in Microbiology, Vol. 14

  5. Study of 32 new phage tail-like bacteriocins (pyocins) from a clinical collection of Pseudomonas aeruginosa and of their potential use as typing markers and antimicrobial agents

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Adaptation of clinical isolates of Klebsiella pneumoniae to the combination of niclosamide with the efflux pump inhibitor phenyl-arginine-β-naphthylamide (PaβN): co-resistance to antimicrobials

    The Journal of antimicrobial chemotherapy, Vol. 77, Núm. 5, pp. 1272-1281

  2. Development of an Anti-Acinetobacter baumannii Biofilm Phage Cocktail: Genomic Adaptation to the Host

    Antimicrobial Agents and Chemotherapy, Vol. 66, Núm. 3

  3. Genomic Analysis of Molecular Bacterial Mechanisms of Resistance to Phage Infection

    Frontiers in Microbiology, Vol. 12

  4. Phenotypic and genomic comparison of klebsiella pneumoniae lytic phages: Vb_kpnm-vac66 and vb_kpnm-vac13

    Viruses, Vol. 14, Núm. 1

  5. Reverse Transcription-Loop-Mediated Isothermal Amplification-CRISPR-Cas13a Technology as a Promising Diagnostic Tool for SARS-CoV-2

    Microbiology spectrum, Vol. 10, Núm. 5, pp. e0239822

  6. The role of PemIK (PemK/PemI) type II TA system from Klebsiella pneumoniae clinical strains in lytic phage infection

    Scientific Reports, Vol. 12, Núm. 1

  7. What are the options for treating infections by persister-forming pathogens?

    Environmental Microbiology, Vol. 24, Núm. 10, pp. 4500-4504

  8. What is the fate of the biofilm matrix?

    Environmental Microbiology, Vol. 24, Núm. 10, pp. 4495-4499

2021

  1. Crispr-cas, a revolution in the treatment and study of eskape infections: Pre-clinical studies

    Antibiotics, Vol. 10, Núm. 7

  2. Enhanced antibacterial activity of repurposed mitomycin C and imipenem in combination with the lytic phage vB_KpnMVAC13 against clinical isolates of klebsiella pneumoniae

    Antimicrobial Agents and Chemotherapy, Vol. 65, Núm. 9

2020

  1. (p)ppGpp and its role in bacterial persistence: New challenges

    Antimicrobial Agents and Chemotherapy, Vol. 64, Núm. 10

  2. Genomic analysis of 40 prophages located in the genomes of 16 carbapenemase-producing clinical strains of Klebsiella pneumoniae

    Microbial Genomics, Vol. 6, Núm. 5, pp. 1-18